Page 75 - Portuguese Journal - SPORL - Vol 61. Nº1
P. 75
Figure 1
Risk of bias assessment graph and summary
NPS in the Gevaert 2013, POLYP 1, and POLYP to a mean difference of -13.59 (95% CI: -17.77,
2 studies, compared to the use of placebo. The -9.42; P<0.00001) points in the SNOT-22 in the
Lund-Mackay Score was only analyzed in the Bachert 2017 and SYNAPSE studies, compared
Gevaert 2013 study and the mean difference to the use of placebo.
was -4.7 points, although this result was not With regard to the extension of the disease, the
statistically significant (P=0.06). use of mepolizumab led to a mean difference
of -0.85 (95% CI: -1.16, -0.54; P<0.00001) points
Mepolizumab in the NPS in the Gevaert 2011 and SYNAPSE
The effects of mepolizumab were evaluated in studies, compared to the use of placebo.
the Gevaert 2011, Bachert 2017, and SYNAPSE
studies (18–20), and the SNOT-22 was used Benralizumab
in the Bachert 2017 and SYNAPSE studies, The effects of benralizumab were evaluated in
while the NPS was used in the Gevaert 2011 the NCT03450083 and OSTRO studies (21,22)
and SYNAPSE studies. No study presented and the three parameters (SNOT-22, NPS, and
valid data for analysis regarding the Lund- Lund-Mackay Score) were evaluated by both
Mackay Score. With regard to the impact on studies. In terms of the impact on the quality
the quality of life, the use of mepolizumab led of life, the use of benralizumab led to a mean
Volume 61 . Nº1 . March 2023 75
